1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 22 FEBRUARY 2016

Cancer Drug News 22 FEBRUARY 2016

  • February 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Stage Set For Next Checkpoint Inhibitor Battle
Industry Trend Analysis - Ibrance Earnings Potential Unlocked Further
Industry Brief - OBI-822/821 Phase II/III Trial Fails To Meet Primary Endpoint In MBC
Industry Brief - Novartis' PKC412 Granted FDA Breakthrough Therapy Status For AML Subtype
Industry Trend Analysis - CAR-T Validation Increasing Confidence
Industry Brief - Aranesp Phase III Study Meets Primary Endpoint In MDS Patients
Industry Brief - Apogenix Secures Funding To Develop APG101 For Glioblastoma
Industry Brief - eFFECTOR Increases Funds To Advance Anti-Cancer Candidate
Industry Trend Analysis - National Cancer Moonshot Mirrors Current Oncology Trends
Industry Brief - BMS/Dana-Farber Cancer Institute Collaborate On I-O RPM Programme
Industry Brief - Myriad Collaborates With Tesaro/Merck On Companion Diagnostic Research
Industry Brief - Helsinn/Mundipharma Enter Deal For Anamorelin In Northern Europe
Industry Brief - Cancer Conferences - May 2016

Table Of Contents

Cancer Drug News 22 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.